Option chain shows key data for OKYO Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for OKYO Pharma.

OKYO Pharma (NASDAQ:OKYO) Stock, Option Chain

OKYO Pharma

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AIXI

ATXI

DPRO

ELAB

GLPG

MIRA

OKYO

PMNT

RNLX

SPRC

STEC

SVMH

TCJH

TLIS

TRSG

TVGN

Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Indianapolis,-,Circa,July,2019:,Conagra,Brands,Manufacturing,Plant.,Conagra

Intraday Update

ASNS

ASTH

BDRX

BRCC

BSFC

CGBS

CING

CLNN

ETWO

IGMS

ISPC

KZIA

LGVN

LNTH

LUCY

MSTR

NAAS

POOL

QURE

RBBN

SOUN

TBIO

TERN

VLCN

VRPX

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Penny Stocks

Small Cap

ABBV

AEHR

AKAN

BCAN

BCLI

CIFR

COOT

CYTO

CZOO

EGOX

ESPR

FLGC

FRGE

GDRX

IVVD

JWEL

LABP

LASE

LCID

LDOS

LICN

LICY

LPRO

MASI

MLGO

NKTX

OCGN

OTRK

SGMT

SINT

SLRX

SOND

STIM

SWVL

URGN

VMEO

XTLB

Shares of  Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

OKYO Pharma Ltd

Press Releases

Goldman Small Cap Research Publishes New Research Report on OKYO Pharma Limited

OKYO Pharma Announces Chairman and CEO Acquire Shares

OKYO Pharma Announces OK-101 Officially Assigned USAN : Urcosimod

Health Care

General

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma to Present at the Bio International Convention

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

C4 Therapeutics

Coherus Oncology

Climb Bio

Coya Therapeutics

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Elutia

Entera Bio

ESSA Pharma

EXoZymes

Forte Biosciences

HilleVax

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Surrozen

TScan Therapeutics

Tenaya Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Comments

OKYO Pharma

OKYO Pharma (OKYO) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell